Viking Therapeutics, Inc.VKTX
Buy moreBuy more on a dip to our buy price, which is under today's $28.
- 1 good· Room to target
- 4 to watch· Earnings miss
$27.66−0.78 (−2.74%)
Price at 3:03 PM ET
After hours · opens in 17h 23mNext open: Friday, Nov 13, 9:30 AM ETNASDAQ · Healthcare · Biotechnology · Mid-size company
The price we'd buy VKTX at comes with a free account
It also has the whole brief, the scorecard and how the call has moved.A free account gets it on three stocks you pick, plus three long research reports a month.
What would change it
Sources
- Yahoo Finance daily closes to Nov 11
Any one could move it to Keep
Compared with the S&P 500
24 points
worse in one day
54 points
worse in five trading days
−31.9% in a yearsince Nov 11, 2025
The news behind our call
- Viking’s SUNRISE Phase 3 studies move VK2735 toward approval.
VK2735 showed meaningful weight loss in Phase 2.
Broad strength across healthcare can keep investor attention on Viking.
What changed
Viking Therapeutics announced two Poster Presentations at ObesityWeek® 2026 on Nov 9.
Overview
What it does
Viking Therapeutics, Inc. tracked for oral and injectable metabolic, obesity, and liver-disease pipeline research.
- It burned $462.6M of free cash in the last twelve months.
- It holds $959.8M in cash and investments against $254.7M of debt, which leaves $705.1M of net cash.
Key figures
- Net income
- −$627M
- EPS (diluted)
- −$5.41
- Return on equity
- -96.4%
- Return on capital
- -52.1%
- Debt / equity
- 0.43
- Current ratio
- 7.27
- Buyback yield
- -3.55%
Key facts
- Company value
- $3.4B
- Today's range
- 27.5028.56
- Past year's range
- 24.2142.13
- Yesterday's close
- $28.44